Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

78.52
+1.431.85%
Post-market: 79.000.4800+0.61%19:30 EDT
Volume:588.38K
Turnover:46.42M
Market Cap:6.13B
PE:79.31
High:80.22
Open:78.72
Low:77.33
Close:77.09
52wk High:82.94
52wk Low:35.20
Shares:78.02M
Float Shares:39.94M
Volume Ratio:1.09
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9900
EPS(LYR):0.7500
ROE:14.04%
ROA:8.05%
PB:9.37
PE(LYR):104.69

Loading ...

Kiniksa Pharmaceuticals Q2 Product Revenue Rises on Arcalyst Sales

Reuters
·
Jul 28

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.28

MT Newswires Live
·
Jul 28

Kiniksa Q2 FY26 Net Income Rises 42.7% to $25.4 Million; Revenue Climbs 55.4% to $243.6 Million

Reuters
·
Jul 28

Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate

Benzinga Earnings
·
Jul 28

Kiniksa Pharmaceuticals Q2 EPS USD 0.3

THOMSON REUTERS
·
Jul 28

Kiniksa Pharmaceuticals Q2 Product Revenue USD 243.6 Million

THOMSON REUTERS
·
Jul 28

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

THOMSON REUTERS
·
Jul 28

Kiniksa Pharmaceuticals International, PLC Expected to Post Earnings of 30 Cents a Share - Earnings Preview

Reuters
·
Jul 24

Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Stock Fully Valued?

Simply Wall St.
·
Jul 09

Kiniksa Files Form 3 for Chief Strategy Officer Dhiraj H. Malkani

Reuters
·
Jul 07

Kiniksa Pharmaceuticals is Maintained at Outperform by Wedbush

Dow Jones
·
Jun 29

Kiniksa price target raised to $72 from $59 at Wedbush

TIPRANKS
·
Jun 29

Kiniksa Pharmaceuticals International, Plc : Wedbush Raises Target Price to $72 from $59

THOMSON REUTERS
·
Jun 29

Wedbush Raises Price Target on Kiniksa Pharmaceuticals International to $72 From $59, Keeps Outperform Rating

MT Newswires Live
·
Jun 29

US High Growth Tech Stocks to Watch

Simply Wall St.
·
Jun 24

Kiniksa Pharmaceuticals International (KNSA) Stock Could Be 18% Undervalued After Strong Buy Upgrade

Simply Wall St.
·
Jun 17

Kiniksa Pharmaceuticals held annual shareholder meeting

Reuters
·
May 30

Kiniksa Pharma to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 30

Kiniksa shareholders waive share conversion rights above 49.9% voting stake

Reuters
·
May 27

Kiniksa Pharmaceuticals announces annual shareholder meeting

Reuters
·
May 09